Possible renoprotective mechanisms of SGLT2 inhibitors

Treatment with a sodium glucose cotransporter 2 (SGLT2) inhibitor in patients with chronic kidney disease reduces the renal risk independent of changes in blood glucose concentrations and blood pressure. However, the precise mechanism responsible for this SGLT2 inhibitor-induced renoprotective effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishiyama, Akira, Kitada, Kento
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033659/
https://www.ncbi.nlm.nih.gov/pubmed/36968844
http://dx.doi.org/10.3389/fmed.2023.1115413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033659/
https://www.ncbi.nlm.nih.gov/pubmed/36968844
http://dx.doi.org/10.3389/fmed.2023.1115413

Ejemplares similares